我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

奥扎格雷用于冠状动脉支架术后预防急性、亚急性血栓形成(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2006年第6期
页码:
668-671
栏目:
临床研究
出版日期:
2006-12-25

文章信息/Info

Title:
Ozagrel prevents patients acute thrombosis and subacute thrombosis in patients following primary percutaneous coronary intervention
作者:
刁繁荣; 吕安林; 李军杰; 苑媛; 陈丹; 胡小菁; 胡艳
第四军医大学西京医院心血管内科， 陕西 西安 710032
Author(s):
DIAO Fan-rong;  Lv An-lin;  LI Jun-jie;  YUAN Yuan;  CHEN Dan;  HU Xiao-jing;  Hu Yan
Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi′an,Shaanxi 710032, China
关键词:
奥扎格雷; 冠状动脉疾病; 介入治疗; 血栓形成
Keywords:
ozagrel;  coronary artery disease;  interventional therapy;  thrombosis
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 评价奥扎格雷在冠状动脉支架置入术（PCI）后预防急性、亚急性血栓形成的有效性和安全性。方法 2005年2月～2006年2月不稳定型心绞痛、陈旧性心肌梗死和急性心肌梗死行PCI术患者497例，采用随机双盲方法，分为A、B两组，A组199例，B组298例。B组采用常规抗凝、抗小血板治疗，A 组在B 组治疗基础上加用奥扎格雷（160 mg）静脉滴注，2次/d，连续使用4 d。术后观察两组患者临床症状、心电图和实验室指标变化。结果 ① A组发生急性血栓1例，无亚急性血栓形成，血栓发生率0.5%(1/199)；B组发生急性血栓3例，亚急性血栓8例，血栓发生率3.7%(11/298),两组血栓发生率有统计学意义（P<0.05）。② A 组终点事件发生率为1.0%（2/199），B 组终点事件发生率为4.0%（12/298）。两组终点事件比较无统计学意义。③ 术前、术后1月，两组血细胞、血凝指标变化无显著差异。④ A组穿刺局部血肿发生率为2.0%(4/199)，B组穿刺局部位血肿发生率为3.0% (9/298)，两组均无其它出血等不良反应。结论 PCI术后使用奥扎格雷能有效、安全预防急性、亚急性血栓形成。
Abstract:
AIM To evaluate the efficacy and safety of ozagrel administration in preventing acute thrombosis and subacute thrombosis in patients who were treated with percutaneous coronary intervention (PCI). METHODS From February of 2005 to February of 2006, 497 cases with unstable angina, and old and acute myocardial infarction were treated with PCI. All the cases were randomly divided into group A (199 cases) and group B (298 cases). Group B were treated regularly with anticoagulant and antiplatelet drug. Group A received the same treatment as group, plus a 4day administration of ozagrel (160mg, iv, twice/d). The clinical characteristics, changes of electrocardiogram and laboratory indexes were observed. RESULTS ①One case with acute stent thrombosis was observed and the incidence of thrombosis in group A was 0.5%(1/199). Eleven cases with stent thrombosis were observed in Group B (3 acute thrombosis and 8 subacute thrombosis) and the incidence of thrombosis in group B was 3.7% (11/298). The difference of incidence of thrombosis between group A and group B was significant (P<0.05). ②Two end events happened in group A (2/199) and 12 end events happened in group B (12/298) . ③The changes of indexes of hemagglutination and blood cells were not significant before and after PCI . ④Four cases with haematoma were observed in group A (4/199) while eight patients with haematoma were observed in group B (9/298). No other hemorrhage phenomenon was observed. CONCLUSION The use of ozagrel after PCI can effectively and safely prevent acute thrombosis and subacute thrombosis.

参考文献/References

［1］ Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithromboticdrug regimens after coronaryartery stenting. Stent Anticoagulation Restenosis Study Investigators［J］. N Engl J Med, 1998,339（23）:1665-1671.

［2］ Tolleson TR, Newby LK, Harrington RA, et al. Frequency of stent thrombosis after acute coronary syndromes(from the SYMPHONY and 2nd SYMPHONY trials) ［J］. Am J Cardiol, 2003,92（3）:330-333.

［3］ Zheng NX,Soto H, Adachi I,et al. Pharmacokinetic and pharmacodynamic studies of a thromboxane synthetase inhibitor, ozagrel, in rabbits［J］. Biol Pharm Bull,1995,18(12):1738-1743.

［4］ buccellati C, Ciceri P,Ballerio R,et al. Evaluation of the effects of antithromboxane agents in plateletvessel wall interaction［J］. Eur J Pharmacol,2002,443(1-3):133-141.

［5］ 涂昭辉, 吴宣树. 阿司匹林在心血管病患者中的抵抗现象［J］. 心脏杂志, 2003,15(6):534-536.

［6］ Gurbel PA, Bliden KP, Hiatt BL, et al . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity［J］. Circulation, 2003,107(23) :2908-2913.

［7］ Nguyen TA,Diodati JG,Pharand C.Resistance to clopidogrel: a review of the evidence［J］. J Am Coll Cardiol, 2005,45(8):1157-1164.

［8］ 谭真, 黄德嘉, 张敏,等. 美洛昔康与小剂量阿司匹林联用对心血管病患者前列环素血栓烷A2平衡的影响［J］. 心脏杂志, 2005,17(4):376-379,382.

［9］ Oishi M,Mochizuki Y,Hara M,et al. Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction［J］. Clin Neuropharmacol, 1996, 19(6):526-531.

［10］Dogne JM,de Leval X,Benoit P,et al. Thromboxane A2 inhibition: therapeutic potential in bronchial asthma［J］. Am J Respir Med, 2002,1(1):11-17.

［11］Sueda S,Kohno H,Inoue K, et al. Intracoronary administration of a thromboxane A2 synthase inhibitor relieves acetylcholineinduced coronary spasm［J］. Circ J, 2002,66(9):826-830.

［12］Lev EI,Patel RT,Maresh KJ,et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance［J］. J Am Coll Cardiol,2006,47(1):27-33.

备注/Memo

备注/Memo:
收稿日期：2006-04-12.通讯作者：吕安林，副主任医师，主要从事冠心病介入治疗研究 Tel：(029)84771040 Email: lvanlin@fmmu.edu.cn 作者简介：刁繁荣，主治医师，硕士生Tel：(029)84773464 Email:diaofr@fmmu.edu.cn
更新日期/Last Update: